Cinnamyl-3,4-dihydroxy-α-cyanocinnamate is a potent inhibitor of 5-lipoxygenase

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 205-213

  Pergola, Carlo ^a   Jazzar, Bianca ^b   Rossi, Antonietta ^c   Buehring, Ulrike ^b   Luderer, Susann ^b   Dehm, Friederike ^a   Northoff, Hinnak ^d   Sautebin, Lidia ^c   Werz, Oliver ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CINNAMYL 3,4 DIHYDROXY ALPHA CYANOCINNAMATE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MONOCYTE; NEUTROPHIL; NONHUMAN; PLEURISY; PRIORITY JOURNAL; RAT; SHOCK; SINGLE DRUG DOSE; THROMBOCYTE;

ADULT; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CAFFEIC ACIDS; CELLS, CULTURED; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOXYGENASE INHIBITORS; MICE; PLEURISY; RATS; RATS, WISTAR;

EID: 79959497076     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180794     Document Type: Article

References (40)

1. Bäck M (2009) Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 15:3116-3132.
2. Blois MS (1958) Antioxidant determinations by the use of a stable free radical. Nature 181:1199-1200.
3. Brash AR (1999) Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274:23679-23682.
4. Brungs M, Rådmark O, Samuelsson B, and Steinhilber D (1995) Sequential induction of 5-lipoxygenase gene expression and activity in Mono Mac 6 cells by transforming growth factor beta and 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 92:107-111.
5. Bürger F, Krieg P, Marks F, and Fürstenberger G (2000) Positional- and stereo-selectivity of fatty acid oxygenation catalysed by mouse (12S)-lipoxygenase isoenzymes. Biochem J 348:329-335.
6. Byrum RS, Goulet JL, Griffiths RJ, and Koller BH (1997) Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 185:1065-1075. (Pubitemid 27136799)
7. Chen XS, Sheller JR, Johnson EN, and Funk CD (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372:179-182. (Pubitemid 24347837)
8. Cho H, Ueda M, Tamaoka M, Hamaguchi M, Aisaka K, Kiso Y, Inoue T, Ogino R, Tatsuoka T, and Ishihara T (1991) Novel caffeic acid derivatives: extremely potent inhibitors of 12-lipoxygenase. J Med Chem 34:1503-1505.
9. de Carvalho DD, Sadok A, Bourgarel-Rey V, Gattacceca F, Penel C, Lehmann M, and Kovacic H (2008) Nox1 downstream of 12-lipoxygenase controls cell proliferation but not cell spreading of colon cancer cells. Int J Cancer 122:1757-1764. (Pubitemid 351413421)
10. Deschamps JD, Gautschi JT, Whitman S, Johnson TA, Gassner NC, Crews P, and Holman TR (2007) Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem 15:6900-6908. (Pubitemid 47451802)
11. Deschamps JD, Kenyon VA, and Holman TR (2006) Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem 14:4295-4301.
12. Fischer L, Szellas D, Rådmark O, Steinhilber D, and Werz O (2003) Phosphorylation-and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredoxtype inhibitors. FASEB J 17:949-951.
13. Galati G, Sabzevari O, Wilson JX, and O'Brien PJ (2002) Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 177:91-104. (Pubitemid 34786247)
14. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR, and Newcomer ME (2011) The structure of human 5-lipoxygenase. Science 331:217-219.
15. Guo QY, Miao LN, Li B, Ma FZ, Liu N, Cai L, and Xu ZG (2011) Role of 12-lipoxygenase in decreasing P-cadherin and increasing angiotensin II type 1 receptor expression according to glomerular size in type 2 diabetic rats. Am J Physiol Endocrinol Metab 300:E708-E716.
16. Kälvegren H, Andersson J, Grenegård M, and Bengtsson T (2007) Platelet activation triggered by Chlamydia pneumoniae is antagonized by 12-lipoxygenase inhibitors but not cyclooxygenase inhibitors. Eur J Pharmacol 566:20-27. (Pubitemid 46805092)
17. Kaplan AP (2002) Clinical practice. Chronic urticaria and angioedema. N Engl J Med 346:175-179.
18. Kim JA, Gu JL, Natarajan R, Berliner JA, and Nadler JL (1995) A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol 15:942-948.
19. Kimura Y, Okuda H, and Arichi S (1985) Studies on scutellariae radix; XIII. Effects of various flavonoids on arachidonate metabolism in leukocytes. Planta Med 51:132-136.
20. Kühn H and O'Donnell VB (2006) Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 45:334-356. (Pubitemid 43818131)
21. Kuwata H, Nakatani Y, Murakami M, and Kudo I (1998) Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J Biol Chem 273:1733-1740. (Pubitemid 28133704)
22. McMillan RM and Walker ER (1992) Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 13:323-330.
23. Nadel JA, Conrad DJ, Ueki IF, Schuster A, and Sigal E (1991) Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. J Clin Invest 87:1139-1145.
24. Naito Y, Sugiura M, Yamaura Y, Fukaya C, Yokoyama K, Nakagawa Y, Ikeda T, Senda M, and Fujita T (1991) Quantitative structure-activity relationship of catechol derivatives inhibiting 5-lipoxygenase. Chem Pharm Bull (Tokyo) 39:1736-1745.
25. Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, Samuelsson B, Rådmark O, Sautebin L, and Werz O (2008) ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci USA 105:19881-19886.
26. Pergola C and Werz O (2010) 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 20:355-375.
27. Peters-Golden M and Henderson WR Jr (2007) Leukotrienes. N Engl J Med 357:1841-1854.
28. Pontiki E and Hadjipavlou-Litina D (2008) Lipoxygenase inhibitors: a comparative QSAR study review and evaluation of new QSARs. Med Res Rev 28:39-117. (Pubitemid 350274961)
29. Rådmark O, Werz O, Steinhilber D, and Samuelsson B (2007) 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32:332-341. (Pubitemid 47021417)
30. Sekiya K and Okuda H (1982) Selective inhibition of platelet lipoxygenase by baicalein. Biochem Biophys Res Commun 105:1090-1095. (Pubitemid 13219433)
31. Stern N, Kisch ES, and Knoll E (1996) Platelet lipoxygenase in spontaneously hypertensive rats. Hypertension 27:1149-1152. (Pubitemid 26142813)
32. Suzuki H, Ueda T, Juránek I, Yamamoto S, Katoh T, Node M, and Suzuki T (2000) Hinokitiol, a selective inhibitor of the platelet-type isozyme of arachidonate 12-lipoxygenase. Biochem Biophys Res Commun 275:885-889.
33. Tornhamre S, Elmqvist A, and Lindgren JA (2000) 15-Lipoxygenation of leukotriene A(4). Studies Of 12- and 15-lipoxygenase efficiency to catalyze lipoxin formation. Biochim Biophys Acta 1484:298-306.
34. Wedi B and Kapp A (2001) Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications. BioDrugs 15:729-743.
35. Wen Y, Nadler JL, Gonzales N, Scott S, Clauser E, and Natarajan R (1996) Mechanisms of ANG II-induced mitogenic responses: role of 12-lipoxygenase and biphasic MAP kinase. Am J Physiol 271:C1212-C1220.
36. Werz O (2002) 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 1:23-44.
37. Werz O, Bürkert E, Samuelsson B, Rådmark O, and Steinhilber D (2002) Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonu-clear leukocytes. Blood 99:1044-1052. (Pubitemid 34527142)
38. Whitman S, Gezginci M, Timmermann BN, and Holman TR (2002) Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. J Med Chem 45:2659-2661. (Pubitemid 34595235)
39. Yamamoto S, Katsukawa M, Nakano A, Hiraki E, Nishimura K, Jisaka M, Yokota K, and Ueda N (2005) Arachidonate 12-lipoxygenases with reference to their selective inhibitors. Biochem Biophys Res Commun 338:122-127. (Pubitemid 41540546)
40. Yoshimoto T and Takahashi Y (2002) Arachidonate 12-lipoxygenases. Prostaglandins Other Lipid Mediat 68-69:245-262. (Pubitemid 35247400)